The company has developed an imaging product that does not use energy transmission or projection to the body to obtain an image - the information is obtained from the low frequency vibrations produced by the body itself or through an external resonance catalyst
The Israeli start-up company Deep Breeze received CE approval for the marketing of its first product, VRIXP, in Europe. The company has developed an imaging product with a new approach: instead of transmitting energy or projection to the body to obtain an image, the information is obtained from the low-frequency vibrations produced by the body itself or through an external resonance catalyst.
Deep Breeze's solution is considered unique because it does not involve projection, and still allows a two-dimensional image of organs, even while moving. The first development of the technology is intended for the imaging of the lungs, and is designed to replace the static imaging of the chest.
Using sensors that are attached to the body and check the vibrations, the monitor device can also provide additional data besides an image, such as the state of lung function; The device is also able to respond to the situation of pathological lung sounds or other breathing problems in real time. In this way, the company's device can report on the success of the respiratory system in hospitals or verify that the inhalation treatment is successful.
"The VRIXP system adds a new and revolutionary dimension to lung transplant patients, and to the evaluation of invasive operations in the lung," said Prof. Mordechai Kramer, director of the Institute of Lung Diseases at the Rabin Medical Center in Petach Tikva. "Now we will be able to evaluate lung function in a more effective and non-invasive way."
According to the company's CEO, Dr. Yigal Kushni, the technology is also suitable for imaging and measuring other organs such as the heart, and can give a real-time image of the entire heart, compared to other products that can only give a partial image of the heart. In the future, this device will be able to replace the respiratory and heart monitors in hospitals."
The system costs 60 thousand euros in the first stage. To date, Deep Breeze has raised about 12 million dollars since its establishment in 2001, and it employs 50 people. Investors in the company include the venture capital fund Vita Life.
